7th Eurasian Hematology Oncology Summit
2020 Efficacy Data on Targeted Therapies in CLL: Do We Need to Combine Rituximab With Ibrutinib for Better PFS? How Does Venetoclax/Obinutuzumab Affect Survival Rates? What’s the Therapeutic Potential of Acalabrutinib?
Comments 0
Login to view comments.
Click here to Login
